Pimecrolimus

• A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 1… Recruiting
  2023-508099-12-00 Phase III 7 countries Sanofi-Aventis Recherche & Developpement
• Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis Recruiting
  2024-519081-49-00 Phase II 9 countries Novartis Pharma AG
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended
  2023-508096-36-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended
  2022-502937-24-00 Phase III 18 countries Abbvie Deutschland GmbH & Co. KG
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended
  2023-506558-20-00 Phase III 6 countries Sanofi-Aventis Recherche & Developpement
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2022-501196-41-00 Phase III 4 countries Sanofi-Aventis Recherche & Developpement
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2023-506557-38-00 Phase III 7 countries Sanofi-Aventis Research & Development

Showing 1–7 of 7 trials